Sees Q4 revenue $292.7M-$307.7M, consensus $302.6M. Sees Q4 adjusted EBITDA $216M-$220M. “As the fourth quarter begins, member activity continues to remain healthy. In light of our strong results over the first nine months of the year, as well as our expectations for member engagement over the remainder of the year, we’re pleased to raise our full year guidance,” said Anevski.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PGNY:
- Progyny launches pregnancy, postpartum, menopause programs
- Trump Weekly: U.S. threatens China with 100% tariff over rare earth controls
- Trump Trade: Trump says cost of GLP-1 drugs to come down ‘pretty fast’
- Trump’s possible IVF action an incremental positive for Progyny, says BofA
- White House to seek to make IVF more accessible, NY Times reports